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INTRODUCTION

Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed
childhood psychiatric disorder in the United States, functionally impairing approximately
3-5% o f the preadolescent population (American Psychiatric Association [APA], 1994).
ADHD is characterized by a persistent pattern o f inattention and/or impulsivityhyperactivity that is more frequent and severe than typically observed in individuals at
comparable levels o f development (APA, 1994).
The prevalence o f ADHD among adults was not recognized until recently. It had
previously been assumed that children “outgrow” ADHD symptoms by adolescence
(Laufer & Denhoff, 1957; Arnold, Strobl & Weisenburg, 1972). Recent studies have
acknowledged that symptoms of ADHD persist into adolescence. In one such study, over
70% o f children with ADHD were found to have met criteria for the disorder in
adolescence (Barkley, 1990). Furthermore, studies have reported that 5-60% o f children
with ADHD continue to experience residual or full symptoms o f this disorder into
adulthood (Biederman et al., 1993; Gittelman, Mannuzza, Shenker, & Bonagura, 1985;
Wilens, Prince, Biederman, Spencer & Frances, 1995).
Children diagnosed with ADHD may be unable to sit still and pay attention in
class, have poor peer relations, and exhibit disruptive behavior. These behaviors can
often lead to academic, social and behavioral difficulties (APA, 1994). The symptoms of
ADHD in adults appear to be developmentally related to those in children and include
manifestations o f inattention and distractibility, impulsivity and hyperactivity (Ward,
1
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Wender, & Reimherr, 1993). The common presenting symptoms for adults diagnosed
with ADHD include inattention, poor concentration, distractibility, daydreaming,
boredom, forgetfulness, impulsivity, intrusiveness, low frustration tolerance, and temper
tantrums, (e.g., Faraone et al., 2000,Wilens, Biederman et al. 1995). In addition, adults
diagnosed with ADHD have been shown to have high rates o f psychopathology, social
dysfunction, academic difficulties, and occupational failure, (Biederman et al, 1993),
substance abuse (Levin & Kleber, 1995; Wilens, Prince, et al., 1995) and depression
(Alpert et al., 1996).

Pharmacological Treatment o f ADHD

To address the clinical symptoms o f ADHD, 85-95% o f individuals diagnosed
with ADHD receive pharmacological treatment, and approximately 70-90% o f the
psychostimulant products prescribed for ADHD are methylphenidate-based (e.g.,
Concerta ®, Metadate ®, Ritalin®; Robison, Sclar, Skaer & Galin, 1999; Zarin, Suarez,
Pincus, Kupersanin & Zito, 1998; Zito et al., 2000). Methylphenidate (MPH) has been
shown to have positive effects in children across a wide range o f domains (DuPaul,
Barkley & Conner, 1998; Greenhill, 1998) including: academic productivity and accuracy
(DuPaul, Barkley & McMurray, 1994; Elia, Welsh, Gulotta & Rapoport, 1993);
fidgetiness and motor restlessness (DuPaul et al., 1994); parent and teacher behavior
ratings (Barkley, 1991); aggression and other antisocial behavior (Bukstein & Kolkso,
1998) and social functioning and peer relations (Barkley & Cunningham, 1979; Barkley,
1989).

2
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Although the efficacy o f MPH has been documented in children and adolescent
populations, the efficacy o f MPH in adult populations has not been clearly established.
Despite the more than 200 controlled studies o f stimulant treatment in children with
ADHD (for reviews see Wilens & Biederman, 1992; Swanson, McBumett, Wigal, &
Pfiffner, 1993; MTA Group, 1999), there have been only six controlled studies of
stimulants in adults diagnosed with ADHD (for review see Wilens, Spencer &
Biederman, 2002; Wilens, Biederman, et al., 1995). Controlled outcome studies
examining the efficacy o f MPH in adults diagnosed with ADHD have yielded
inconsistent results. Overall, the results of these studies suggest that the response rate in
adults with respect to ADHD symptom reduction is more ambiguous than those found in
children, ranging from 25% to 78% (Wood, Reimherr, Wender & Johnson, 1976; Mattes,
Boswell & Oliver, 1984; Wender, Reimherr, Wood & Ward, 1985; Gualtieri, Ondrusek
& Finley, 1985; Shekim, Asamow, Hess, Zaucha & Wheeler, 1990; Spencer et al., 1995).
The most robust findings resulted from a randomized placebo-controlled
crossover study o f MPH in 23 adults diagnosed with ADHD using DSM-III-R defined
criteria (Spencer et al., 1995). Results indicated that the overall response rate for ADHD
symptoms, as measured by the ADHD Rating Scale (Barkley, 1990), was significantly
higher during MPH treatment as compared to placebo (78% vs. 4%; p<0.0001). Overall,
the variability observed across these six controlled studies could be attributed to
differences in diagnostic criteria, methodology, MPH doses, comorbid psychiatric
disorders, and outcome measures (Wilens, Biederman, et al., 1995). Yet, across studies,
participants who responded favorably reported experiencing improved attention, and
decreased restlessness, impulsivity and impatience (Shekim et al., 1990), and less

3
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anxiety, anger and irritability (Wood et al., 1976). Several o f these controlled studies
suggest that MPH treatment for adults can lead to robust, dose-dependent improvement in
ADHD symptoms (Biederman & Spencer, 2002).
Despite the equivocal results, MPH appears to be associated with improvements
in attention span, behavior, cognitive aptitude, memory processing, mood stability, and
sensorimotor coordination in adults (Greenhill, 1995). The amelioration o f the symptoms
o f ADHD may lead to improvements in everyday abilities, academic or occupational
performance and social adaptability (Bhandary, Fernandez, Gregory, Tucker & Masand,
1997). Thus, in spite o f the limited number o f controlled studies examining the efficacy
o f MPH, it appears to be well tolerated and is associated with improvement o f symptoms
in adults diagnosed with ADHD.

Mechanism o f Action

MPH is associated with a wide range o f clinically beneficial effects, yet the
specific mechanisms by which the drug alters behavior have not been conclusively
determined. From a neuropharmacological standpoint, MPH is believed to exert clinical
effects by acting on noradrenergic and dopaminergic pathways by blocking dopamine
(DA) and norepinephrine (NE) transporters (Solanto, 2000). By increasing the
intrasynaptic dopamine by blocking the dopamine transporter, it is hypothesized that
MPH attenuates deficits in inhibitory control and working memory that are hallmarks of
ADHD (Greenhill, 1998).
MPH also demonstrates dopaminergic effects in the ventral tegmental area and
nucleus accumbens via the mesolimbic pathway, thus MPH has been hypothesized to

4
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affect behavior by altering behavioral reinforcement processes (Solanto, 2000). Several
studies have provided some support for this theory o f the behavioral mechanism o f action
o f MPH. For example, one study demonstrated that MPH functions as an establishing
operation by altering the rewarding properties o f different kinds o f stimuli in children
with ADHD (Northup, Fusilier, Swanson, Roane & Borrero, 1997). While other studies
have reported that when compared to non-drug conditions, MPH also changes the manner
in which children with ADHD allocate their behavior across alternatives that produce
rewards at different rates (e.g., Kollins, Lane, & Shapiro, 1997; Murray & Kollins, 2001).

Abuse Potential

The neuropharmacological profile o f MPH is similar to that o f other commonly
abused stimulants such as cocaine and d-amphetamine (Hoffman & Lefkowitz, 1996).
As such, concern regarding the abuse potential o f MPH has arisen (see Kollins,
MacDonald & Rush, 2001 for review). Recently, attention has focused on the misuse and
abuse o f MPH among adolescents, college students, and parents o f children with
prescriptions for MPH for the treatment of ADHD (e.g., Drug Enforcement
Administration, 2000; Liana & Crimson, 1999; Safer, 2000; Popper, 1995). One study
examined the rates o f MPH misuse in adolescents assessed at an outpatient substance
abuse treatment facility and reported that there was a significant increase in MPH misuse
from 1992-1996 (Marsh, Key & Payne, 2000). Also, in a survey o f school-aged
children, one out o f six reported having been approached to buy, sell or trade MPH
(Musser, Ahmann, Mundt, Broste, Mueller-Rizner, 1998), while a recent survey of
college-aged students revealed that 16% o f survey responders (N=283) reported trying

5
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MPH recreationally, and 12.7% reported using the drug intranasally (Babcock & Byrne,
2000).
Several case reports have also suggested more clinically significant patterns of
MPH misuse, with users taking the drug to induce euphoria by crushing the tablet and
administering it intranasally or intravenously (Fulton & Yates, 1988; Jaffe, 1991; Parran
& Jasinski, 1991; Weiner, 2000). Though some individuals may use MPH to achieve
euphoric drug highs, others may use MPH to improve attention and alertness. Among
college students, MPH is reportedly used to stay awake to “party” longer, improve study
skills by increasing mental concentration, or to increase alertness and decrease fatigue
following “all-nighters” (Babcock & Byrne, 2000). Moreover, anecdotal reports o f MPH
use generally involve MPH being used to enhance social interactions or academic
performance (Drug Enforcement Administration, 2000). Thus, the misuse o f MPH has
been documented and may be increasing.
Laboratory studies support the abuse potential o f MPH in nonhumans and
humans. MPH is behaviorally similar to other abused drugs such as d-amphetamine and
cocaine (for review see Kollins et al., 2001). Specifically, in relation to these other
stimulants, MPH produces comparable discriminative stimulus effects (e.g., Perkins,
Eckman, & MacPhail, 1991; Wood & Emmett-Oglesby, 1988; Rush, Kollins, Pazzaglia,
1998; Kollins, Shapiro, Newland & Abramowitz, 1998), subjective effects (e.g., Chait,
1994; Heishman & Henningfield, 1991; Martin, Sloan, Sapira & Jasinski, 1971; Roehrs,
Papineau, Rosenthal & Roth, 1999; Rush et al., 1998; Rush, Essman, Simpson & Baker,
2001; Smith & Davis, 1977) and reinforcing effects (e.g., Aigner & Balster, 1979;

6
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Bergman et al., 1989; Risner & Jones, 1975; Chait, 1994; Roehrs, Papineau, Rosenthal &
Roth, 1999; Rush et al., 2001).
One paradigm for assessing the abuse potential o f a drug involves measuring its
subjective effects in human participants. The subjective effects o f a drug are considered
to be strongly correlated with a drug’s abuse potential (Jaskinski & Henningfield, 1989).
Specifically, if a drug is associated with ratings o f drug-liking, euphoria, or produces
ratings comparable to other known drugs o f abuse, the drug is believed to have abuse
potential. Methylphenidate exerts clear participant rated effects across instruments when
compared to placebo in human adults (e.g., Chait, 1994; Heishman & Henningfield,
1991; Martin, Sloan, Sapira & Jasinski, 1971; Roehrs, Papineau, Rosenthal & Roth,
1999; Rush et al., 2001; Rush et al., 1998; Smith & Davis, 1977). These studies
demonstrated that MPH increased ratings o f “Arousal,” “Anxiety,” “High,” “Talkative,”
“Euphoric,” “Like Drug,” and “Like to Take Again” (for review see Kollins et al., 2001).
Although MPH is associated with subjective effects in adults, it is not associated
with clear participant-rated effects in children (Kollins et al., 1998; MacDonald &
Kollins, 2000). Rather, the patterns o f participant-rated effects obtained in children were
variable, and clear trends were not observed. The idiosyncratic participant-rated effects
observed in children could be due to a developmental difference in the ability to selfreport drug effects.
Another paradigm used to measure the abuse potential o f a drug involves
assessing a drug’s reinforcing effects by determining whether it maintains self
administration (Brady, Heinz, & Ator, 1990). MPH has been shown to function as a
reinforcer itself as demonstrated by self-administration paradigms in nonhuman species

7
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(Aigner & Balster, 1979; Johanson & Schuster, 1975; Risner & Jones, 1975). Although
the reinforcing effects of a drug are considered to be one o f the most powerful predictors
o f abuse, only three published studies have directly examined the reinforcing effects o f
MPH in humans (Chait, 1994; Roehrs et al., 1999; Rush et al., 2001). The results o f
these studies do not provide conclusive evidence with respect to the reinforcing effects of
MPH in humans. O f these published studies, one study did not report consistent
reinforcing effects (Chait, 1994); one study reported significant reinforcing effects
compared to placebo using a progressive-ratio procedure (Rush et al., 2001); and one
study reported reinforcing effects under the specific environmental conditions of sleep
deprivation (Roehrs et al., 1999).
In the first study, Chait (1994) measured the subjective and reinforcing effects of
methylphenidate in 35 non-drug abusing human participants using a choice procedure.
Participants were administered MPH and placebo on alternating days. Following this
sampling phase was a choice day, wherein the participants could choose between MPH
(20-40 mg), placebo or no capsules/neither drug. The results yielded inconsistent
reinforcing effects. Out of 105 total choices across participants (three choices each),
MPH was chosen 29 (27.6%) times, placebo was chosen 9 (8.6%) times, and no capsules
were chosen on 67 (63.8%) occasions.
The second study assessed the reinforcing effects of MPH (20-40 mg), damphetamine (10-20 mg) and placebo in eight healthy adults using a modified
progressive-ratio schedule, which are frequently used to assess the reinforcing effects of
abused drugs (Rush et al., 2001). During sampling sessions participants ingested eight
identical capsules, wherein each capsule contained 12.5% o f the total dose. During self-

8
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administration sessions, participants could earn capsules by responding on a progressiveratio task. Participants had eight opportunities to work on a computer task in order to
earn all or some o f the eight capsules administered during the sampling session. In order
to earn the first capsule, participants were required to click the mouse 50 times. The
number o f mouse clicks required to earn additional capsules doubled (e.g., 100, 200, 400,
800, 1600, 3200, 6400). Participants ingested all o f the capsules they had earned after
completing the progressive-ratio schedule. The dependent measure in this study was the
break-point, which is the last ratio completed. Results indicated that the highest dose of
MPH (40 mg), and both doses o f d-amphetamine, increased the break-point values
significantly above placebo, demonstrating that MPH functioned as a reinforcer in these
healthy adult participants.
Finally, in the third study, the impact o f sleepiness on the reinforcing effects of
MPH was studied in six healthy volunteers 21-30 years o f age (Roehrs et al., 1999). On
sampling days, the participants received 10-mg o f MPH or placebo after four or eight
hours in bed and then, on separate choice days after four or eight hours in bed,
participants chose their preferred capsule. The results indicated that MPH was chosen
significantly more after four hours in bed (88%) as compared to choices made following
eight hours in bed (29%). The authors interpreted the findings as supportive of the idea
that the reinforcing effects o f a drug are influenced by environmental circumstances
(Roehrs et al., 1999). As such, in healthy adult volunteers sleep deprivation functioned as
an establishing operation that altered the reinforcing effects o f MPH.
Another recently completed study examined the reinforcing effects o f MPH in
five children diagnosed with ADHD (MacDonald & Kollins, 2000). Results

9
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demonstrated that the difference between the number o f choices for MPH, Placebo and
Neither was statistically significant (X =9.6; /><0.01). Out o f 30 total choices across all
participants (six choices for each o f five participants), MPH was chosen 18 times (60%).
Placebo and Neither were each chosen six times (20%). This study was the first to
document the reinforcing effects of MPH in a sample o f individuals receiving the drug
for clinical purposes.
Relatively few studies have examined the reinforcing effects o f psychoactive
drugs in individuals who receive them for clinical purposes (Roache, Stanley, Creson &
Schmitz, 1996; Roache, Stanley, Creson, Shah, & Meisch, 1997; deWit, Uhlenhuth,
Hedeker, McCracken & Johanson, 1986). As described previously, MacDonald &
Kollins (2000) examined the reinforcing effects o f MPH in children diagnosed with
ADHD. However, to date this is the only study that has experimentally assessed the
reinforcing effects o f MPH in individuals diagnosed with ADHD who are prescribed the
drug for clinical purposes. In the past decade, the therapeutic use o f MPH has increased,
leading to debates surrounding the prescription rates and safety o f this stimulant drug
(Rappley, 1997). There continues to be concern surrounding the use of stimulant
medications to treat individuals, specifically children, diagnosed with ADHD.
Specifically, critics argue that MPH is over-prescribed and is inherently dangerous
(Safer, 2000; Safer, Zito, & Fine, 1996). Thus, in light o f these arguments, it is critical to
evaluate the reinforcing effects and abuse potential o f MPH in a clinical sample.

10
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PURPOSE OF PRESENT STUDY

The purpose o f the present study was to examine the reinforcing effects and
participant-rated effects o f MPEt in adults diagnosed with ADHD. Such research may
provide important information regarding: (a) the behavioral mechanism o f action o f MPH
and how the drug interacts with other environmental events to produce meaningful
clinical change, and (b) insight into the abuse potential o f this drug in clinical
populations.

METHODS

Participants

Participants for this study were 7 males (ages 18-22) and 3 females (ages 20-21).
The participants were recruited through local physicians and psychologists, recruitment
flyers, and word of mouth on the basis of two criteria: (1) an established diagnosis of
ADHD, and (2) a current prescription for MPH for the treatment o f symptoms associated
with ADHD. All participants had been receiving MPH treatment for at least six months
prior to selection for the study.
To corroborate the ADHD diagnostic status o f participants and to ensure a
homogeneous group, participants were required to receive a score o f 36 or higher on the
Wender Utah Rating Scale (WURS; Wender et al., 1985), and obtain a T-score o f 65 or
higher on the ADHD symptoms scale of the Conners Adult ADHD Rating Scale
(CAARS; Conners, Erhardt, & Sparrow, 1999). Participants were excluded if they were
taking any other type of psychoactive medication, exhibited any gross neurological,

11
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sensory or motor impairment, had a history o f other significant learning or psychiatric
problems, or any current severe psychiatric disturbances (e.g., suicidality, homicidality,
criminality). A total of 17 individuals were screened and 7 were excluded for the
following reasons: not currently receiving MPH treatment (4), not willing to receive
placebo (2), did not meet diagnostic criteria on the CAARS (1). Table 1 shows
demographic information for the participants.
Participants received monetary compensation for their participation in the 13
sessions. Participants received $5 for each session and an additional $20 for completing
all 13 sessions. In addition, by returning their daily questionnaires, participants were
entered into weekly drawings for the opportunity to win gift certificates and coupons to
local businesses and restaurants.
The Human Subjects Institutional Review Board at Western Michigan University
approved this work (Appendix A).

Dependent Variables

Drug Preference

Drug choice was the primary dependent measure. The number o f times one
option (MPH, Placebo, Neither) was chosen over the other served as an indicator o f its
relative reinforcing effects (e.g., de Wit, 1991).

Participant-Rated Effects

In order to assess the subjective effects o f MPH, the participants completed
various self-report measures. The participant-rated effects are important in that they may
12
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Table 1
Participant Demographics
P articipant

Sex

Age

Dose

CAARS
(ADHD Total)

WURS
(Total Score)

1

F

21

10-mg

T=81

37

2

F

20

10-mg

T=83

59

3

F

20

15-mg

T=67

46

4

M

18

20-mg

T=71

59

5

M

22

20-mg

T=72

54

6

M

20

30-mg

T=74

59

7

M

20

10-mg

T=90

63

8

M

19

10-mg

T=78

36

9

M

21

20-mg

T=88

79

10

M

21

20-mg

T=75

54

be useful in predicting reinforcing and clinical efficacy o f MPH. The participant-rated
effects were assessed pre-drug administration, 1.5 hours and 4 hours post-drug
administration. The participant-rated effects measures are as follows:
1.

Participant-Rated Effects Scale (PRES). The Participant Rated Effects Scale

(PRES) is a 25-item scale developed for this study to assess the subjective effects o f
MPH in adults diagnosed with ADHD. This scale was developed to streamline the
assessment of subjective effects and to provide the least intrusive and time intensive
assessment of participant-rated effects in these volunteers as they were requested to
complete these forms in their natural environment.
Items from the questionnaire (Appendix B) were rated on a 5-point scale (1-5)
where each numeric value corresponded to a phrase describing the frequency or intensity
o f the item (1= not at all, 2= a little bit, 3 = moderately, 4= quite a bit, 5= extremely).
13
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Participants were instructed to rate each item according to how they felt “at that
moment.” Items on this form were derived from four primary sources: (1) Addiction
Research Center Inventory (ARCI; Martin et ah, 1971); (2) Profile of Mood States
(POMS; McNair, Lorr & Droppleman, 1971); and (3) Conners Adult ADHD Rating
Scale (CAARS, Conners, Erhardt, & Sparrow, 1999 and the DSM-IV (APA, 1994).
Items included those that had been used to measure the participant-rated effects o f many
drugs and are sensitive to the effects o f stimulants (e.g., Heishman & Henningfield, 1991;
Roache, Grabowski, Schmitz, Creson, & Rhoades, 2000). The items from the CAARS
and the DSM-IV included symptoms o f ADHD and were selected because o f clinical
utility in determining the effects o f stimulant medications in this population.
2. End of the Day Questionnaire. This five-item questionnaire was administered
approximately four hours after capsule ingestion to measure the overall effect o f the drug
received. Participants rated “Drug Strength,” “Drug Liking,” “Good Effects,” “Bad
Effects,” and “Like to Take Again” on a 5-point scale (0 = Not at all, 1 - A little bit, 2 =
Moderately, 3 = Quite a bit, 4 = Very much). Participants were also prompted to provide
reasons for their pill choice, and to report any untoward effects.
3. Daily Activity Record. Participants used this form to record any academic or
job requirements that occurred during the four hours post-drug administration.
Participants also rated their performance on these tasks.

Procedures

Volunteers participated in 13 sessions. The first session was a screening session
wherein the participant completed self-report assessment measures. In addition, medical

14
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history, comorbid mental health diagnoses, length o f time on MPH and dosing
information were obtained. Participants provided informed consent to participate in the
study and all subjects received medical clearance for participation from their prescribing
physician. After the participant received medical clearance from the prescribing
physician, a collaborating physician from Western Michigan University Health Center
wrote prescriptions for placebo pills and the participant’s normal dose o f MPH.
All drugs were prepared in a standardized manner by a pharmacist at the
University Health Center who had experience preparing medications for similar research
and clinical activities. The participant’s maintenance dose o f MPH and an inert placebo
were each prepared in opaque capsules (size 01) to ensure that the enclosed substance
was unknown to the subject and to the researcher. Each participant’s maintenance dose
was encapsulated in one capsule, so that only one capsule was administered at a time.
The capsules were placed in separate bottles labeled as “Bottle A” and “Bottle B” with
the MPH represented by one letter (e.g., “A”) and the placebo being the other (e.g., “B”).
The capsule letter assignments were varied across participants. However, the participants
were informed that the same lettered capsule always contained the same substance.

Screening Session

During the screening session, participants completed the WURS and the CAARS,
and provided information regarding medication history. If entry criteria were met,
participants provided consent to contact their physicians to obtain medical clearance. An
independent physician served as a consultant on this study and provided the prescriptions
following documentation of medical clearance from the participant’s individual
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physician. During the screening session, the researcher and the participant discussed the
participant’s class and/or work schedule in order to schedule the next 12 sessions so as to
minimize the interference in the individual’s work and class performance. Thus, the
specific time that participants arrived at the laboratory was arranged on an individual
basis in order to minimize the influence o f this study on their class and/or work
schedules.
Participants were asked to maintain their normal caffeine and nicotine use and to
refrain from eating one hour before the session. Participants were provided with a
standard light snack upon arrival to the laboratory. They were asked to refrain from
taking their MPH prescription for at least four hours prior to coming into the laboratory.
There were three sessions each week for four weeks. The methods used in the present
study are modeled after similar drug self-administration studies (e.g., Chait, Uhlenhuth &
Johanson, 1987; deWit, Uhlenhuth & Johanson, 1984; Johanson, Kilgore & Uhlenhuth,
1983; Johanson & Uhlenhuth, 1982).

Sampling Sessions

The first four sessions were sampling sessions. The sampling sessions were
designed to allow participants to experience the effects o f the two drug conditions (MPH
and Placebo) on the basis o f which they would subsequently make their drug choice.
On the first sampling day, upon arriving at the laboratory participants were given
a standard light snack (juice and breakfast bar). Participants then completed the
participant-rated effects scale. During the first sampling session, after completing the
participant-rated effects questionnaire, participants received either placebo or MPH in a
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capsule labeled “Pill A” or “Pill B.” In the second sampling session, participants
received the other substance in a capsule labeled with the other letter. Participants also
received a card labeled with the same letter as the pill administered as a reminder of
which capsule they received that day. Participants were instructed to associate the effects
o f the capsule with its letter label. Capsule letter assignments varied across participants,
and the order in which placebo and MPH were scheduled in the sampling sessions was
counterbalanced across subjects and within-subjects across weeks. As noted previously,
the actual letter codes used were varied across participants and they were instructed that
capsules with the same letter always contained the same substance. The third and fourth
sampling sessions followed the same capsule administration order.
After receiving the capsule, the participants were free to leave the laboratory and
resume daily activities. They were given two questionnaire packets and were instructed
to complete one packet 1.5 and 4 hours following capsule ingestion. Because these
participants had demanding class and work schedules, in addition to being diagnosed
with ADHD, they were asked to complete questionnaires only twice post-drug
administration so as to minimize interference with their daily functioning. Participants
were required to return their packets to the laboratory by 5:00 p.m., at which time they
received their ticket for the weekly drawings.

Choice Sessions

The remaining eight sessions were choice sessions. In the choice sessions,
following the completion o f questionnaires, participants were presented three cups for the
drug choice administration: one labeled “Pill A” (or whatever letter corresponded to
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MPH), one labeled “Pill B” (or whatever letter corresponded to placebo), and an empty
cup labeled “C.” The participant chose either to ingest “Pill A,” to ingest “Pill B” or to
take neither capsule. The use of a “Neither” option was included to replicate prior studies
o f the reinforcing effects o f MPH (Chait, 1994) and to provide a more reliable measure o f
the reinforcing efficacy o f the chosen substance (Spiga & Roache, 1997). This choice
procedure is a technique that has been used to measure the reinforcing effects o f a
number o f different drugs, in a range o f contexts and with various subject populations
(e.g., deWit & Griffiths, 1991; Foltin & Fischman, 1991; Johanson & deWit, 1989).
Following each choice, the participant was presented with the appropriate letter-matched
card. After capsule administration, the participant was free to leave the laboratory and
resume daily activities. The procedures for collecting participant-rated effect
questionnaires were identical to those used in the sampling sessions.

DATA ANALYSIS

Reinforcing Effects

The number o f times MPH, Placebo and Neither were chosen were taken as
indicators o f their positive reinforcing properties (deWit, Uhlenhuth & Johanson, 1984).
The reinforcing effects o f MPH were assessed by calculating the total number of choices
o f MPH, placebo, and neither across participants and examining the proportion o f choices
with a chi-square analysis. “Choosers” were defined as individuals who selected MPH
on at least 5 out o f 8 occasions.
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Participant-Rated Effects

The participant-rated effects were analyzed by transforming the 25-item
questionnaire into three composite scores: (1) ADHD composite (10 items), (2) Mood
composite (12 items), and (3) Stimulant composite (3 items) (Appendix C). The
composite scores were averaged across “MPH,” “Placebo,” and “Neither” sessions for
each subject at each o f the three time periods (pre, 1.5 hour, and 4 hour) for both
sampling and choice sessions. The change from baseline ([post-drug administration
scores]-[pre-drug administration scores]) was also computed using raw scores for each
composite for MPH sessions, Placebo sessions and Neither sessions for sampling and
choice sessions. The effect size (d) was calculated by dividing the raw score difference
by the standard deviation o f the measure (Cohen, 1977). The effect size scores obtained
for the ADHD symptom composite, the Mood composite and the Stimulant Effects
composite for MPH choosers were compared to the effect scores obtained for the nonMPH choosers (i.e., placebo and non-choosers) across sampling sessions.
Data from the sampling sessions were analyzed to in a two-way analysis o f
variance (Time x Choice) to compare the participant-rated effects obtained by MPHchoosers and non-choosers. In addition, a two-way analysis o f variance (Drug x Group)
was used to compare the participant-rated effects obtained by MPH-choosers and non
choosers under MPH and Placebo conditions. During choice sessions, participants
determined whether they ingested MPH, Placebo or neither. Thus, because participants
were not exposed to the same number o f MPH, Placebo and no-drug days, data from the
choice days were not analyzed statistically.
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The End o f Day Questionnaire ratings were analyzed using paired t-tests to
compare ratings on each item following MPH and Placebo across all sessions and
separately across sampling and choice sessions.

RESULTS

Reinforcing Effects

The results of the choice sessions were analyzed by examining the percentage o f
MPH choices per subject (See Figure 1). Out o f 80 total choices across all participants
(eight choices each), MPH was chosen 40 times (50%), placebo was chosen 26 times
(32.5%), and neither was chosen 14 times (17.5%). A chi-square analysis found that the
number of choices of MPH, Placebo and Neither differed significantly (A2 =52.484,
/KO.OOl).

100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00

-1
-

-

-

MPH

Placebo
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Figure 1. The Percentage o f Choices across Participants.
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According to the criteria used by Chait (1994), Participants 1, 3, 6, 7 and 10 were
classified as “MPH choosers.” The remaining participants were classified as “Non
choosers.” Specifically, Participants 2, 5 and 8 chose placebo more often than MPH, and
Participants 4 and 9 did not demonstrate reliable choice patterns (See Table 2). When
examining the number of MPH, Placebo and Neither choices among MPH-choosers and
non-choosers, MPH-choosers selected MPH significantly more often than non-choosers
(77.5% vs. 22.5%; F i ,8=24.82,/?<0.001). In addition, MPH-choosers chose Placebo
significantly less often than non-choosers (7.5% vs. 57.5%; F iig=13.11,/K0.01). There
were no significant differences with respect to Neither choices (See Figure 2).

Table 2
Participant Choice Patterns
P articipant

M PH

Placebo

N either

1

6

0

2

2

0

5

3

3

8

0

0

4

4

1

3

5

1

7

0

6

7

1

0

7

5

2

1

8

2

6

0

9

2

4

2

10

5

0

3
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Figure 2. The Percentage o f Choices for MPH-Choosers and Non-Choosers.

Participant-Rated Effects

Effect size scores indicated that participants who subsequently were MPHchoosers differed significantly from participants who were non-choosers with respect to
participant-rated effects obtained during sampling sessions. Specifically, subsequent
MPH-choosers exhibited greater reduction in ADHD symptoms (d= - 0.93), negative
mood (d= - 0.92) and a decrease in stimulant effects (d=1.09) at 1.5 hours post drug
administration than the non-choosers. Baseline score differences indicate that MPHchoosers reported higher levels o f ADHD symptoms than non-choosers (d=0.76), but did
not differ significantly on other composite scores. These large effect sizes indicate that
subsequent MPH-choosers and non-choosers differed significantly with respect to their
responses to MPH and Placebo. Specifically, participants who experienced a significant
reduction in ADHD symptoms and negative mood during sampling sessions were more
likely to select MPH during choice sessions.
22
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Results from the two-way ANOVA indicate that relative to placebo, MPH was
associated with a significant decrease in ADHD symptoms among MPH-choosers ( F i^ =
8.01, p<0.01). The two-way interaction (Drug x Group) was also significant (Fi, 56 =3.50,
p<0.06). Moreover, when compared to non-choosers, MPH-choosers reported a
significant decrease in stimulant effects (Fj, 56 =8.68,/?<0.01). This suggests that
participants who reliably chose MPH reported a significant decrease in ADHD symptoms
and in stimulant drug effects during sampling sessions, while non-choosers did not report
reliable changes across sampling sessions. There were no statistically significant
differences with respect to time, although visual inspection o f the data suggests that the
effects were greatest 1.5 hours after MPH ingestion (See Figure 3).
Results of the pairwise t-tests examining the items on the End o f Day
questionnaire indicated that, across participants, when compared to placebo MPH was
associated with higher ratings o f “Drug Strength” (r(9)=3.59,/?<0.01) and “Good Effects”
(r(9)=2.61,£><0.05) (See Figure 4). There were no significant differences among MPHchoosers and non-choosers, or with respect to dose.
Although statistical analyses suggests that group differences between MPH«

choosers and non-choosers exist, visual inspection o f individual participant-rated effects
suggests that there are variable drug effects across participants with respect to ADHD,
Mood and Stimulant Effects associated with MPH, Placebo and Neither days. In
addition, there is variability with respect to the drug effects observed during sampling and
choice sessions. Figures 5-10 present the ADHD, Mood and Stimulant Effects
composites for each individual participant across drug and no-drug conditions for both
sampling and choice sessions.
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Figure 3. Participant-related Effects across Participants.
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Figure 4. End-of-Day Ratings across Participants.

With respect to the ADHD Composite, MPH-choosers tended to exhibit larger
discrepancies between MPH and Placebo sessions (Figures 5). Specifically, Participants
1, 6, 7 and 10 evidenced large discrepancies between ratings obtained following MPH
and Placebo during sampling sessions, which may have contributed to subsequent MPH
choices. Although a MPH-chooser, Participant 3 did not evidence significant
discrepancies between ratings obtained under MPH and Placebo conditions, suggesting
that the participant-rated effects did not influence Participant 3 ’s MPH choices.
Participants 2, 4, 5, 8 and 9, who were non-choosers, did not evidence any significant
differences between ratings obtained following MPH and Placebo sessions (Figure 6).
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Figure 5 A flD Composites for MPH-Choosers.
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Figure 6. ADHD Composites for Non-Choosers.
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With respect to the Mood Composite, there was considerable variability across
participants. Based on visual inspection o f data, Mood ratings o f MPH-choosers do not
appear to be reliable predictors o f MPH choice (Figure 7). Specifically, Participant 1
demonstrated a significant difference with respect to MPH and Placebo, with MPH being
associated with a decrease in negative mood. Participant 3 did not evidence any
significant discrepancies between MPH and Placebo. Participant 6 exhibited significant
differences with respect to MPH and Placebo at the 4-hour rating, but ratings at pre-drug
and 1.5 hours post-drug administration were comparable for MPH and Placebo sessions.
Participants 7 and 10 demonstrated differences in MPH and Placebo ratings during choice
sessions, yet sampling session ratings were comparable.
The Mood Composites o f non-choosers suggest that MPH is associated with
negative mood ratings (Figure 8). Specifically, Participant 2, 5 and 9 demonstrated
significant discrepancies between MPH and Placebo during sampling sessions, such that
MPH was associated with higher negative mood ratings. Participants 4 and 8 did not
exhibit significant differences between MPH and Placebo during sampling sessions;
however, Participant 8 exhibited significantly higher negative mood following MPH
choice sessions.
Similar to Mood ratings, the Stimulant Effects Composites were variable across
participants. Specifically, among the MPH-choosers (Figure 9), Participants 6 and 10
reported significant discrepancies between MPH and Placebo such that MPH was
associated with a decrease in Stimulant ratings, while Placebo increased Stimulant
Ratings. Participant 3 reported higher baseline Stimulant ratings on Placebo sampling
days, but when compared to MPH, the magnitude o f change was similar. Participant 7
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Figure 7. Mood Composites for MPH-Choosers.
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Figure 8. Mood Composites for Non-Choosers.
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Figure 9. Stimulant Effects Composites for MPH-Choosers.
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also demonstrated higher baseline Stimulant ratings on Placebo sampling days, but
reported a greater decrease in ratings following Placebo as compared to MPH.
W ith respect to the Stimulant ratings o f non-choosers (Figure 10), Participants 2,
4 and 5 did not exhibit significant differences between MPH and Placebo. Participant 8
and 9 exhibited higher baseline Stimulant ratings on MPH days, and reported significant
decreases in ratings following MPH administration. In addition, Participant 9 reported a
significant increase in Stimulant ratings following placebo.

DISCUSSION

Results demonstrate that the differences between the number o f MPH, Placebo
and Neither choices across subjects was statistically significant, and MPH was chosen
more frequently than placebo or no capsules by 5/10 participants. Moreover, MPH was
chosen 77.5% o f the time by MPH-choosers, as compared to being chosen 22.5% of the
time by non-choosers. These findings are commensurate to the results obtained in
previous studies examining reinforcing effects in healthy adults and children diagnosed
with ADHD.
This study has several important implications. First, it adds to a sparse literature
on the reinforcing effects o f MPH in humans and is the first to study these effects in a
sample o f individuals receiving the drug for clinical purposes. To date, the literature is
inconclusive with respect to whether methylphenidate exerts reinforcing effects in
humans. One study failed to report consistent reinforcing effects (Chait, 1994); one study
reported reinforcing effects under specific conditions o f sleep deprivation (Roehrs et al.,
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Figure 10. Stimulant Effects Composites for Non-Choosers.
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1999); and one study reported significant reinforcing effects compared to placebo using a
progressive-ratio procedure (Rush et al., 2001).
The present study may be most similar to Roehrs et al. (1999) such that the
reinforcing effects o f MPH are context-specific. As such, effect size scores suggest that
during sampling sessions MPH-choosers had higher baseline ADHD symptoms,
demonstrated greater improvement in mood and a greater reduction in ADHD symptoms
upon receiving MPH. Although, the non-choosers reported a reduction in ADHD
symptoms following MPH and Placebo during sampling sessions, MPH-choosers
reported significantly greater ADHD symptom reduction following MPH administration,
and a slight increase in ADHD symptoms following placebo. This suggests that perhaps
the reinforcing effects o f MPH are related to the clinical efficacy o f MPH, such that the
more efficacious MPH was in reducing ADHD symptoms, the more likely it was chosen
over placebo.
Results o f the current study, in addition to previous findings (e.g., Roehrs et al.,
1999; MacDonald & Kollins, 2000) suggest that perhaps the reinforcing effects o f MPH
are expressed only under a particular set o f environmental conditions. For example, in
the current study, anecdotal subject comments suggested that their drug choice was
influenced by the extent of the demands to be placed on them following drug
administration. Specifically, participants reported choosing MPH when they needed to
study or had class. Moreover, participants reported not choosing MPH when they
“wanted to take a nap” or “had nothing to do.” These reports are similar to the work
completed by Silverman and colleagues (Silverman, Kirby, & Griffiths, 1994, &
Silverman, Mumford, & Griffiths, 1994), which demonstrated that the behavioral
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requirements following drug administration (i.e., vigilance or relaxation activities) could
alter the self-administration of stimulants (i.e., caffeine and d-amphetamine) and
sedatives (i.e., triazolam). Based on these findings, the authors suggested that drug selfadministration is related to the changes in environmental conditions. Thus, conditions o f
sleep deprivation, inattention and distractibility may function as establishing operations
that increase the reinforcing efficacy o f MPH. Likewise, the behavioral demands to be
placed on an individual may also influence the reinforcing efficacy o f this stimulant drug.
Continued research examining the conditions associated with the reinforcing
effects o f MPH may also be important from the standpoint o f assessing the abuse
potential o f MPH. The reinforcing effects and subjective effects o f a substance are
typically used to assess the abuse potential o f that drug. Results o f the present study
suggest that it may be necessary to reconceptualize indices used to measure the abuse
potential o f a substance. Most research asserts that if a drug functions as a reinforcer, it
is considered to have considerable abuse liability (Fischman & Mello, 1989). Yet, as
discussed by Roache and colleagues (1997), drug reinforcement in clinical populations is
not always indicative o f abuse potential in the same manner as drug reinforcement in
drug abusers or other non-clinical (or nonhuman) samples. Drug abuse refers to a
repeated pattern o f self-administration that results in functional impairment for the
individual taking the drugs (APA, 1994).
The reinforcing effects o f clinically used agents may necessitate a different
conceptualization o f such drug-taking behavior. Specifically, the reinforcing effects o f a
clinically used agent may reflect therapeutic efficacy, rather than abuse potential. In
these situations, the choice o f drug over placebo may be reinforced by the consequences
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of eliminating aversive stimuli (e.g., anxiety; Roache et al., 1997) or by more positive
consequences, such as being able to work more efficiently, receiving greater praise from
teachers and peers, or getting better grades (as may be the case with ADHD).
In the present experiment, the reinforcing effects o f MPH were associated with a
reduction in seemingly aversive symptoms (e.g., inattention, anxiety, sadness) and an
increase in positive symptoms (e.g., “good effects”). This suggests that choosing to
ingest MPH is associated with clinical efficacy, thus perhaps MPH is not producing
significant clinical effects in non-choosers. Also o f note in this experiment is the pattern
o f subjective effects associated with MPH. A number o f previous studies have
demonstrated that orally-administered MPH as low as 20-mg results in significant
changes in ratings o f “High,” and other effects associated with abuse potential (e.g., Heil
et al., 2002; Kollins, Rush, Pazzaglia, & Ali, 1998; Rush et al., 1998). However, in spite
o f the reinforcing effects reported in the present study, the participant-rated effects of
MPH were not consistent with previous studies. This suggests that perhaps the
participant-rated effects may contribute to a differential profile o f abuse potential of MPH
in individuals diagnosed with ADHD. Moreover, this also suggests that the reinforcing
effects and participant-rated effects o f MPH are not isomorphic, which is consistent with
other studies examining the reinforcing effects and participant-rated effects o f drugs of
abuse (e.g., Roache et al., 1995; Rush et al., 2001).
In addition, research suggests that neuropharmacological differences may
contribute to differential abuse potential in individuals diagnosed with ADHD as
compared to non-diagnosed individuals. Evidence supports the idea that
neuropharmacological differences exist between diagnosed and non-diagnosed
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individuals with respect to dopamine functioning. Specifically, individuals diagnosed
with ADHD differ from non-diagnosed controls with respect to dopamine transporter
(DAT) density, such that DAT was significantly elevated in subjects diagnosed with
ADHD (e.g., Dougherty et al., 1999). These differences in DAT density may contribute
to the expression o f ADHD symptoms and the efficacy o f MPH treatment, ft is possible
that differences in dopamine functioning may influence the abuse potential o f MPH such
that MPH may not exert the same level of abuse potential in individuals diagnosed with
ADHD as compared to non-diagnosed controls (e.g., Volkow et al., 1999, 2002).
Future studies that examine MPH in a context where there are measurable clinical
changes will be important to help clarify the functional role o f the reinforcing effects o f
the drug in this and other samples. Specifically, it is suggested that future work examine
the reinforcing effects o f MPH and concomitant participant-rated effects in diagnosed
and non-diagnosed populations to further explore the role o f clinical effects in the
reinforcing effects o f this stimulant drug.
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Appendix B
Participant-Rated Effects Scale
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Please place an "X" in the appropriate column to indicate how the following words or
phrases describe you AT THIS M OM EN T

!
1
2
3
4

Not at All
(i)

A little Bit
(2)

Moderately
(3)

Quite a Bit
(4)

Happy
Anxious

Tense
Angry
5 Sad

6 Fatigued
7 Unable to concentrate
8 Hungry
9 Energetic
10 Annoyed
11 Focused
12 Forgetful
13 Cheerful
14 Nervous
15 Talkative
16
17
18
19
20
21

Fidgety
Distracted
Restless
Impulsive
Overactive
Inattentive
22 Excited
23 Agitated
24 Irritable
25 Frustrated

|
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Extremely
(5)

Appendix C
Participant-Rated Effects Composites
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ADHD
Unable to Concentrate
Focused*
Forgetful
Talkative
Fidgety
Distracted
Restless
Impulsive
Overactive
Inattentive

Composites
Mood
Happy*
Anxious
Tense
Angry
Sad
Fatigued
Annoyed
Cheerful*
Nervous
Agitated
Irritable
Frustrated

Stimulant Effects
Hungry
Energetic
Excited

Note: All items were rated on a 5-point scale as follows: 1= not at all, 2= a little bit, 3 =
moderately, 4= quite a bit, 5= extremely.
*Reverse-scored
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